RxDoctor Payments Data

Thomas Macmillan, OD

Optometrist · Clinton, SCNPI 1154305910

Payments from drug & device makers

$1,821in general payments, 2019–2025

Across 51 payments — averaging $35.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$653
  • Coopervision Inc.$287
  • Topcon Healthcare, Inc.$241
  • Johnson & Johnson Vision Care, Inc.$180
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$103
  • Oyster Point Pharma, Inc.$88
  • plus $269 from 9 others

What the payments were for

  • Food & beverage$1,80299%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,821 in reported general payments places this provider in the 65th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$31,243
Medicare patients
214
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost23$10,553
RestasisCyclosporine11$7,017
CombiganBrimonidine Tartrate/Timolol13$3,306
Alphagan PBrimonidine Tartrate12$2,354
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$1,759
Latanoprost165$1,055
Travoprost12$712
Prednisolone Acetate21$600
Tobramycin-DexamethasoneTobramycin/Dexamethasone16$492
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$451
Doxycycline Hyclate14$376
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$340
Timolol Maleate27$295
ErythromycinErythromycin Base18$191
Brimonidine Tartrate13$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$23$23,23059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Clinton

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →